MS TOOLKIT...Updates in Research and Treatment...

A resource for informing patients and caregivers about Multiple Sclerosis, its possible causes, effects, and treatments. Get the most current information on new developments, clinical trials and other important matters for anyone dealing with MS.

Saturday, August 02, 2008

Tysabri Product Use Disclaimer




Posted by Cary J. Polevoy at 9:43 AM
Email ThisBlogThis!Share to XShare to FacebookShare to Pinterest
Labels: Biogen Idec/Elan, multiple sclerosis, progressive multifocal leukoencephalopathy (PML), Tysabri
Newer Post Older Post Home

Blog Archive

  • ►  2009 (9)
    • ►  January (9)
  • ▼  2008 (127)
    • ►  December (4)
    • ►  November (4)
    • ►  October (19)
    • ►  September (18)
    • ▼  August (16)
      • BIOMS MEDICAL ANNOUNCES POSITIVE INTERIM ANALYSIS ...
      • Europe assessing Tysabri brain disease reports
      • Prime Therapeutics Releases Annual Drug Trend Insi...
      • World-Class MS Information At The Touch Of A Button
      • Pluristem's PLX-MS Shows Potential Benefit in the ...
      • High risk of conversion to multiple sclerosis pred...
      • IMPAX Reports Positive Results in Phase III Trial ...
      • Expert Opinion Paper - National MS Society Makes R...
      • CARIS REITERATES SELL ON ELAN
      • Tysabri Product Use Disclaimer
      • EDITORIAL COMMENTARY
      • Multiple Sclerosis: New MRI Contrast Medium Enable...
      • Biogen, Elan stand by MS drug after illnesses
      • Adult Stem Cells Reprogrammed To Become Myelin-Mak...
      • Biogen, Elan Report Brain Infection in Tysabri Users
      • Putting Drug Development In Patients' Hands
    • ►  July (13)
    • ►  June (9)
    • ►  May (7)
    • ►  April (17)
    • ►  March (8)
    • ►  February (7)
    • ►  January (5)
  • ►  2007 (354)
    • ►  December (11)
    • ►  November (11)
    • ►  October (34)
    • ►  September (9)
    • ►  August (21)
    • ►  July (21)
    • ►  June (57)
    • ►  May (16)
    • ►  April (25)
    • ►  March (33)
    • ►  February (53)
    • ►  January (63)
  • ►  2006 (209)
    • ►  December (62)
    • ►  November (61)
    • ►  October (46)
    • ►  September (40)

About Me

Cary J. Polevoy
Cary J. Polevoy holds M.B.A and undergraduate degrees from Michigan State University. An active investor since 1965, Mr. Polevoy began his investment career as a stockbroker. He has also been a NYSE Supervisory Securities Analyst, director of research, mutual fund portfolio manager, and CEO/CFO of various small companies. He has worked for Merrill Lynch, EF Hutton, RAC Advisors, Quantum Fund, The Broe Companies, McKinley Medical, among others. Diagnosed with multiple sclerosis in 1995, he is the author of the book, "MS TOOLKIT - THE PATIENTS' & CAREGIVERS' GUIDE TO MULTIPLE SCLEROSIS." DISCLAIMER: While I used to be a securities analyst, portfolio manager and registered investment advisor, I no longer am. Any opinions expressed herein are personal opinions and are not expressed as recommendations, advice or bets.
View my complete profile
Awesome Inc. theme. Powered by Blogger.